Topics

PubMed Journals Articles About "Stopping Nucleos Therapy Continue Nucleos Analogue Chronic Hepatitis" RSS

15:54 EST 27th January 2020 | BioPortfolio

Stopping Nucleos Therapy Continue Nucleos Analogue Chronic Hepatitis PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Stopping Nucleos Therapy Continue Nucleos Analogue Chronic Hepatitis articles that have been published worldwide.

More Information about "Stopping Nucleos Therapy Continue Nucleos Analogue Chronic Hepatitis" on BioPortfolio

We have published hundreds of Stopping Nucleos Therapy Continue Nucleos Analogue Chronic Hepatitis news stories on BioPortfolio along with dozens of Stopping Nucleos Therapy Continue Nucleos Analogue Chronic Hepatitis Clinical Trials and PubMed Articles about Stopping Nucleos Therapy Continue Nucleos Analogue Chronic Hepatitis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Stopping Nucleos Therapy Continue Nucleos Analogue Chronic Hepatitis Companies in our database. You can also find out about relevant Stopping Nucleos Therapy Continue Nucleos Analogue Chronic Hepatitis Drugs and Medications on this site too.

Showing "stopping nucleos therapy Continue nucleos analogue Chronic Hepatitis" PubMed Articles 1–25 of 20,000+

Challenges with stopping long-term nucleos(t)ide analogue therapy in patients with chronic hepatitis B.


Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study.

We aim to explore the effects of nucleos(t)ide analogues (NUCs) on the changes of HBsAg in chronic hepatitis B (CHB) patients.

Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis.

To compare the efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B.


Predictors for relapse after cessation of nucleos(t)ide analogues treatment in HBeAg-negative chronic hepatitis B patients: a meta-analysis.

The aim was to identify the predictors for relapse after the withdrawal of nucleos(t)ide analog (NA) therapy in patients with HBeAg-negative chronic hepatitis B (CHB).

NUCLEOS(T)IDE ANALOG THERAPY OF CHRONIC HEPATITIS B AND LIVER CANCER RISK REDUCTION: BETTER NUCLEOTIDES THAN NUCLEOSIDES?

Comparison of HBV genotypes B and C among chronically HBV-infected patients who received nucleos(t)ide analogues: A multicenter retrospective study.

Hepatitis B virus genotype B (HBV/B) has been reported to have less risk of liver cirrhosis and hepatocellular carcinoma (HCC), but long-term observation has rarely been reported. We aimed to clarify the characteristics of HBV/B in nucleos(t)ide analogue (NA)-treated patients in an area where HBV/B is more prevalent than in other areas of Japan.

Genetic variations in the CXCR5 gene decrease the risk of clinical relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B.

Discontinuation of nucleos(t)ide analogue (NA) therapy in patients with chronic hepatitis B (CHB) remains a global but controversial problem. Clinical outcomes of NA cessation depend on the interplay between viral factors and host immunity. Recent studies have shown that genetic polymorphisms might influence the immune response in chronic HBV infection. A total of 33 single-nucleotide polymorphisms (SNPs) from 16 genes (BCL6, CD40, CD40L, CTLA-4, CXCL13, CXCR5, ICOS, IL-21, HLA-C, NTCP, UBE2L3, STAT4, IFN-...

Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro.

Hepatitis E is a global public health problem. Ribavirin (RBV) and pegylated interferon alpha are currently administered to cure hepatitis E. Recently, in combination with RBV, sofosbuvir (SOF), an anti-hepatitis C virus nucleotide analog, is also given to patients with chronic hepatitis E. However, this combinatorial therapy sometimes fails to achieve a sustained virological response. In this study, we used 27 antiviral compounds, including 15 nucleos(t)ide analogs, for in vitro screening against a genotyp...

Early Serum HBsAg Drop Is a Strong Predictor of HBeAg Seroconversion and HBsAg Loss to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients with Prior Nucleos(t)ide Analogue Exposure.

BACKGROUND High rates of HBeAg and/or HBsAg seroconversion or clearance have been achieved in chronic hepatitis B (CHB) patients receiving pegylated interferon (pegIFN) in addition to ongoing nucleos(t)ide analogue (NUC) treatment. In the present study, we aimed to evaluate HBsAg kinetics to predict HBeAg seroconversion and HBsAg clearance in these patients. MATERIAL AND METHODS A total of 33 HBeAg-positive and 17 HBeAg-negative patients were enrolled between January 2010 and January 2018. At the end of peg...

Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis.

Recent available treatment guidelines are pointing up clearance or seroconversion of hepatitis B e-antigen (HBeAg) as a valuable endpoint in treating HBeAg-positive chronic hepatitis B (CHB) patients. To evaluate the effect of combination therapy [interferon (IFN) plus nucleos(t)ide analogues (NAs)] versus IFN monotherapy on HBeAg seroconversion or seroclearance in HBeAg-positive CHB patients.

Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients.

Improved management of chronic hepatitis B patients with oral nucleos(t)ide analogues has increased the number of these patients who are getting older and have other accompanying comorbidities. These comorbidities frequently require various immunosuppression treatments and/or cytotoxic chemotherapy. Not only the patients who are positive for HBsAg, but also the patients who are positive for isolated anti-HBc are at risk for hepatitis B reactivation during immunosuppression. Prophylactic antiviral treatment ...

Hepatitis flare-related decompensation is associated with better outcomes in patients with chronic hepatitis B.

The effects of baseline hepatitis flares (alanine transaminase level >5 times the upper limit of normal) on the outcomes of cirrhotic chronic hepatitis B (CHB) patients with decompensation treated with nucleos(t)ide analogues (Nucs) remain elusive; thus, we aimed to investigate these effects.

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.

Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary goal of developing agreement on chronic hepatitis B virus (HBV) treatment endpoints to guide clinical trials aiming to 'cure' HBV. Agreement among the conference participants was reached on some key points. 'Functional' but not sterilizing cure is achievable and should be defined as sustained HBsAg loss in addition to undetectable HBV DNA 6 months post-treatment. The primary endpoint of p...

Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries.

Treatment of chronic hepatitis B virus (HBV) infection with entecavir suppresses virus replication and reduces disease progression, but could require life-long therapy. To investigate clinical outcome events and safety associated with long-term treatment with entecavir, we followed patients treated with entecavir or another standard of care HBV nucleos(t)ide analogue for up to 10 years. We assessed long-term outcomes and relationships with virologic response.

Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients.

Recently, the role of albumin-bilirubin (ALBI) score in chronic hepatitis B (CHB) has not been well-understood. We aimed to investigate the association of ALBI score with natural history of chronic HBV infection and treatment response of CHB patients.

Barriers to chronic Hepatitis B treatment and care in Ghana: A qualitative study with people with Hepatitis B and healthcare providers.

Hepatitis B viral (HBV) infection remains an important public health concern particularly in Africa. Between 1990 and 2013, Hepatitis B mortality increased by 63%. In recent times, effective antiviral agents against HBV such as Nucleos(t)ide analogs (NAs) are available. These drugs are capable of suppressing HBV replication, preventing progression of chronic Hepatitis B to cirrhosis, and reducing the risk of hepatocellular carcinoma and liver-related death. Notwithstanding, these treatments are underused de...

HBV-RNA, a new rule for stopping nucleos(t)ide analogues.

Durability of Spontaneous and Treatment-related Loss of Hepatitis B s Antigen.

Clearance of hepatitis B surface antigen (HBsAg) from serum is the most desirable endpoint and a proposed definition of functional cure for hepatitis B virus (HBV) infection. However, little is known about the long-term durability of HBsAg loss, and there is controversy over whether the development of antibodies against HBsAg (anti-HBs) is required for maintenance. We aimed to assess the durability of spontaneous or treatment-related (interferon or nucleos(t)ide analogue [NA]) loss of HBsAg.

HBV virions produced under nucleos(t)ide analogue treatment are mainly not infectious due to irreversible DNA chain termination.

Nucleos(t)ide analogue (NA) have been widely used for the treatment of chronic hepatitis B (CHB). Because viral DNA polymerase lacks proof-reading function (3' exonuclease activity), theoretically, the incorporated NAs would irreversibly terminate viral DNA synthesis. This study explored the natures of nascent HBV DNA and infectivity of progeny virions produced under NA treatment. HBV infectivity was determined by infection of HepG2-NTCP cells and primary human hepatocytes (PHH). The biochemical properties ...

Role of Biomarkers in Guiding Cure of Viral Hepatitis B.

Chronic hepatitis B (CHB) virus infection is a global public health threat affecting approximately 257 million individuals worldwide. Hepatitis B surface antigen (HBsAg) loss has been the classic endpoint to define functional cure and decrease the large pool of individuals with CHB. Current treatments with nucleos(t)ide analogues persistently suppress hepatitis B virus (HBV) deoxyribonucleic acid in most CHB patients, but rarely achieve functional cure. New viral biomarkers, such as quantitative HBsAg, hepa...

Emerging tools in the changing landscape of chronic hepatitis B management.

: The availability of a preventative vaccine, interferon and nucleos(t)ide analogues have provided progress in the control of chronic hepatitis B (CHB). Despite this it remains a major contributor to global morbidity and mortality. Developments in our understanding of the pathogenesis of CHB and the emergence of new therapies are paving the way, as we move towards HBV cure.: We performed bibliographical searches of online databases to review the literature regarding conventional disease phases of CHB. We pr...

The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment.

Sorafenib is currently the first-line therapy for advanced hepatocellular carcinoma (aHCC) patients. However, the outcomes and prognostic factors of sorafenib therapy have not been well investigated. We aimed to investigate the pretreatment factors and outcomes among Taiwanese aHCC patients receiving sorafenib treatment. A total of 347 patients with aHCC and well-compensated liver cirrhosis (Child-Pugh A) status receiving sorafenib were consecutively enrolled from March 2013 through December 2016. Pre-treat...

New Potential Therapies for Chronic Hepatitis B.

A HBV infection is a dynamic disease and long-term liver inflammation contributes to the development of liver cirrhosis and hepatocellular carcinoma. Currently available nucleos(t)ide analogues and pegylated interferon are effective in inhibiting HBV replication but rarely achieve HBsAg clearance. The present article introduces a new definition of HBV cure and several emerging therapies for HBV cure, including direct acting antivirals and immune modulatory antivirals.

Kinetics of hepatitis B surface antigen quasispecies during REP 2139-Ca therapy in HBeAg positive chronic HBV infection.

Chronic HBV infection results in various clinical manifestations due to different levels of immune response. In recent years, hepatitis B treatment has improved by long-term administration of nucleos(t)ide analogues (NUCs) and peg-interferon. Nucleic acid polymers (NAPs; REP 2139-Ca and REP 2139-Mg) are new antiviral drugs that block the assembly of subviral particles, thus preventing the release of HBsAg and allowing its clearance and restoration of functional control of infection when combined with variou...

Minimal increases of serum alpha-fetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy.

In Caucasian patients with compensated cirrhosis due to hepatitis B virus (HBV), the risk of hepatocellular carcinoma (HCC) developing persist despite long-term nucleos(t)ide analogs (NUC) treatment. In the surveillance of this population with persistently normal transaminases due to NUCs, the added value of serum alpha-fetoprotein (AFP) monitoring is poorly defined.


Quick Search